Další formáty:
BibTeX
LaTeX
RIS
@article{1137337,
author = {Baccarani, Michele and Deininger, Michael W. and Rosti, Gianantonio and Hochhaus, Andreas and Soverini, Simona and Apperley, Jane F. and Cervantes, Francisco and Clark, Richard E. and Cortes, Jorge E. and Guilhot, Francois and HjorthandHansen, Henrik and Hughes, Timothy P. and Kantarjian, Hagop M. and Kim, DongandWook and Larson, Richard A. and Lipton, Jeffrey H. and Mahon, FrancoisandXavier and Martinelli, Giovanni and Mayer, Jiří and Mueller, Martin C. and Niederwieser, Dietger and Pane, Fabrizio and Radich, Jerald P and Rousselot, Philippe and Saglio, Giuseppe and Saussele, Susanne and Schiffer, Charles and Silver, Richard and Simonsson, Bengt and Steegmann, JuanandLuis and Goldman, John M and Hehlmann, Ruediger},
article_location = {Washington DC, USA},
article_number = {6},
doi = {http://dx.doi.org/10.1182/blood-2013-05-501569},
keywords = {TYROSINE KINASE INHIBITORS; DIAGNOSED CHRONIC-PHASE; CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; MAJOR CYTOGENETIC RESPONSE; SUBCUTANEOUS OMACETAXINE MEPESUCCINATE; COMPLETE MOLECULAR REMISSION},
language = {eng},
issn = {0006-4971},
journal = {Blood},
note = {Projekt 6. rámce LSHC-CT-2004-503216},
title = {European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013},
volume = {122},
year = {2013}
}
TY - JOUR
ID - 1137337
AU - Baccarani, Michele - Deininger, Michael W. - Rosti, Gianantonio - Hochhaus, Andreas - Soverini, Simona - Apperley, Jane F. - Cervantes, Francisco - Clark, Richard E. - Cortes, Jorge E. - Guilhot, Francois - Hjorth-Hansen, Henrik - Hughes, Timothy P. - Kantarjian, Hagop M. - Kim, Dong-Wook - Larson, Richard A. - Lipton, Jeffrey H. - Mahon, Francois-Xavier - Martinelli, Giovanni - Mayer, Jiří - Mueller, Martin C. - Niederwieser, Dietger - Pane, Fabrizio - Radich, Jerald P - Rousselot, Philippe - Saglio, Giuseppe - Saussele, Susanne - Schiffer, Charles - Silver, Richard - Simonsson, Bengt - Steegmann, Juan-Luis - Goldman, John M - Hehlmann, Ruediger
PY - 2013
TI - European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
JF - Blood
VL - 122
IS - 6
SP - 872-884
EP - 872-884
PB - American Society of Hematology
SN - 00064971
N1 - Projekt 6. rámce LSHC-CT-2004-503216
KW - TYROSINE KINASE INHIBITORS
KW - DIAGNOSED CHRONIC-PHASE
KW - CHRONIC MYELOGENOUS LEUKEMIA
KW - PATIENTS RECEIVING IMATINIB
KW - MAJOR CYTOGENETIC RESPONSE
KW - SUBCUTANEOUS OMACETAXINE MEPESUCCINATE
KW - COMPLETE MOLECULAR REMISSION
N2 - Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels <= 10% at 3 months, <1% at 6 months, and <= 0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph1]>95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
ER -
BACCARANI, Michele, Michael W. DEININGER, Gianantonio ROSTI, Andreas HOCHHAUS, Simona SOVERINI, Jane F. APPERLEY, Francisco CERVANTES, Richard E. CLARK, Jorge E. CORTES, Francois GUILHOT, Henrik HJORTH-HANSEN, Timothy P. HUGHES, Hagop M. KANTARJIAN, Dong-Wook KIM, Richard A. LARSON, Jeffrey H. LIPTON, Francois-Xavier MAHON, Giovanni MARTINELLI, Jiří MAYER, Martin C. MUELLER, Dietger NIEDERWIESER, Fabrizio PANE, Jerald P RADICH, Philippe ROUSSELOT, Giuseppe SAGLIO, Susanne SAUSSELE, Charles SCHIFFER, Richard SILVER, Bengt SIMONSSON, Juan-Luis STEEGMANN, John M GOLDMAN a Ruediger HEHLMANN. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2013, roč.~122, č.~6, s.~872-884. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2013-05-501569.
|
